Global phase III trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in adults 18 years of age and older : A global multi-center, randomized, double-blind, placebo-controlled, adaptive designed phase III clinical trial to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years of age and older Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vec

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

WHO International Clinical Trials Registry Platform - (2021) vom: 30. Aug. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Novel Coronavirus Pneumonia (COVID-19)
Recruitment Status: Recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2021-03-12, Last updated: 2022-11-24

ICTRP ID:

ChiCTR2100044249

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO007574622